A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC 50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain.
A number of groups have focused on development of non-peptidic based small molecule N-type calcium channel blockers aimed at treating inflammatory and chronic pain. 5 We recently reported NP118809 ( Fig. 1) as a potent N-type calcium channel blocker with $110-fold selectivity over the L-type calcium channel and good efficacy in a rodent model of inflammatory pain. 6 As part of our effort to further optimize the development of orally available N-type calcium channel blockers, we tested aryl substitutions on the benzhydryl moiety bound to the piperazine core of NP118809 (Table 1) and also examined a bioisosteric series (Table 2) (Table 4) . The synthesis of compounds with the targeted substitution changes is described in Scheme 1. The starting material diphenylmethanols were synthesized as described in the literature.
7 Treatment with thionyl chloride, followed by coupling with Bocpiperazine, provided a benzhydrylpiperazine that was transformed into product upon reaction with 3,3-diphenylpropionic acid and diphenylmethyl isocyanate. Some experimental details have been published in patent form.
8
The structure-activity analyses of the various chemical series were guided by manual whole-cell patch clamp electrophysiological assay of rat neuronal N-type 9 and L-type 10 ] o containing buffer. Table 1 illustrates the structure-activity trend in N-type inhibition for mono-versus di-substituted phenyl on the diphenylmethylene. Compounds with a single electronwithdrawing substituent on one of the phenyl groups are highly potent N-type channel blockers (compounds [1] [2] [3] [4] [5] [6] [7] [8] [9] . N-type blocking affinity does not appear to depend upon either the exact nature of the electron-withdrawing substituent (CF 3 , Cl, F) or its position on the phenyl ring (Table 1) . For example, compare compound 1, where the trifluoromethyl is at the para-position with compounds 7 and 8 where the chlorine is at the meta-and ortho-positions, respectively. In addition to possessing high N-type blocking activities, this series exhibited a high degree of selectivity over the neuronal L-type calcium channel ($60-1178-fold) .
When matched pairs at the para-position are compared (Table 1), the methyl-and methoxy-substituted phenyl compounds (10 and 11) are consistently less potent N-type blockers than their chloro-and trifluoromethyl counterparts (compounds 1 and 5). These results suggest that electron-donating substituent groups have lower overall affinity for the N-type channel compared to that for compounds containing electron-withdrawing substituents.
As part of the structure-activity studies, the effects of di-substitutions on a single phenyl ring were also explored ( Table 1) . Compounds 14-16 illustrate that di-substitution with electronwithdrawing groups at the ortho-and meta-positions of the phenyl ring does not significantly affect N-type blocking affinity as compared to the single substituent analogues. However, when one of the electron-withdrawing substituents is at the para-position Ntype blocking affinity is lost (compounds 17 and 18).
Compounds 21-27 (Table 2 ) represent the N,4-dibenzhydrylpiperazine-1-carboxamide series (X@CO, Y@NH, Z@CH). The nonsubstituted derivative (compound 21) showed a similar inhibitory activity for N-type calcium channels (est. IC 50 = 0.15 lM) as that of parent compound, NP118809. However, this compound had a higher affinity for the L-type channel resulting in a comparatively lower L-type:N-type selectivity ratio ($12-fold). The substitution of a chlorine group at the 3-position of the benzhydryl moiety (compound 23) led to a 2-fold decrease in N-type blocking activity compared to compound 21, but a better overall L-type:N-type selectivity ($53-fold). Further analogues with di-substitution at the benzhydryl moiety did not show any overall improvement in either N-type blocking affinity or in calcium channel selectivity (compounds 25-27).
Replacement of the carboxamide in compounds 21 with the ethanone group (X@CO, Y@CH, Z@N) (compound 28) showed a dramatic 44-fold decrease in N-type channel blocking activity (Table 2). Contrastingly, either mono-or di-substitution of one of the phenyl groups on the benzhydryl did not significantly affect N-type blocking affinity (compounds 29-34) . Further exploration of the structural activity relationship of derivatives focused around the NP118809 linker moiety (X@CH, Y@CO, Z@N) resulted in compounds with a generally good degree of N-type channel inhibition (compounds 35-41). Unlike that for compound 28, these linker modifications (e.g., compound 35) did not seem to be highly deleterious. The information from this series (21-41) may provide insight into the compound binding conformation at a site on the channel where slight alterations in the linker can have dramatic effect on N-type calcium channel activity.
In order to increase the aqueous solubility of the parent piperazine class, we replaced one aryl group (PhR 1 ) of the benzhydryl moiety with either an N-methylpiperidinyl or piperidinyl group while retaining the second aryl group (PhR 2 ; Table 4 ). The piperidinyl derivatives were synthesized from the corresponding phenyl (pyridinyl-4-yl) methanol using methodology similar to Scheme 1. The synthetic route used for the piperidinyl derivatives is presented in Scheme 2. As described in the literature, 13 phenyl (piperidin-4-yl) methanol was prepared by activating with thionyl chloride and then reacting with Boc-piperazine. The t-butoxycarbonyl protecting group of the product was cleaved with TFA. The deprotected amine was coupled with 3,3-diphenylpropionic acid to yield the target compounds (Scheme 2). The activity of compounds from this series is presented in Table 4. Compound 42, the 4-piperidinyl isomer with no substituent on the nitrogen showed good N-type blocking activity (est.
IC 50 = 0.06 lM) while the N-methylated analogue 43 was an order of magnitude less potent (est. IC 50 = 0.69 lM). Examining further N-methylated piperidinyls (compounds 43-46) showed that compounds 45 and 46 with an electron-withdrawing mono-substitution on one of the phenyl rings to be potent N-type blockers. Eliminating the phenyl group while retaining a piperidinyl group was detrimental towards maintaining N-type channel blocking affinity (compounds 47-49; Table 4 ).
Compounds 2, 4-8, 21 and 46 were subject to in vivo assay for analgesic activity following oral dosing (Table 5 ). The compounds The thermodynamic (equilibrium) solubility was determined using methodology based upon the OECD Water Solubility Method an LC/MS/MS system. Solubility was calculated from plotting a calibration curve using regression analysis of standards and interpolating the saturation solubility of the test compounds from the calibration curve. 15 were tested at a single 30 mg/kg oral dose in the Chung model of neuropathic pain with two behavioral endpoints used: mechanical allodynia and thermal hyperalgesia. 14 In both pain assessments, animals were tested at multiple intervals during a 3 h test period beginning 30 min after test compound administration. One-way ANOVA followed by the Bonferroni test were employed on the original raw data (not normalized) to establish the statistical significance of the differences observed with the baseline value. Data were normalized and expressed as means ± standard errors (SE).
Compounds 5-8 and 21 all showed inhibition of nerve ligation-induced thermal hyperalgesia (ranging from $45% to 98% maximal inhibition; Table 5 ). There did not appear to be a linear correlation between in vitro blocking activity against the N-type channel and analgesic effects in vivo (e.g., compounds 2 and 4). show appreciable efficacy in either measure of analgesia in the SNL model. Taken together, a subset of newly discovered orally administered high affinity N-type antagonists attenuate neuropathic pain although N-type blocking affinity alone cannot predict in vivo efficacy.
In order to ascertain whether general pharmacokinetic characteristics could account in part for the differential in vivo affects observed, representative compounds were selected for profiling in rats (Table 6 ). Compound 2 was well absorbed orally (C max $ 275 ng/ml; bioavailability = 65%), albeit relatively slowly (T max $ 5 h) thus pain responses typically measured 1-3 h postdosing would likely not have reflected the optimal parameters for assessing this particular agent. Comparatively, compound 7 was absorbed more rapidly (T max $ 3 h) and exhibited good bioavailability (F $ 66%) and half-life ($6 h). Compound 21, which exhibited the best overall pain efficacy profile across both mechanical and thermal assessments, exhibited favorable T max ($2 h) and elimination (t 1/2 $ 6 h) although bioavailability was the lowest of the compounds examined (F $ 22%). All three compounds exhibit high affinity in vitro block of the N-type channel target (IC 50 values $ 40-150 nM), good selectivity over the L-type channel, plasma exposures that exceed the N-type target (C max $ 292-518 nM), similar aqueous solubility (Table 3) and other favorable properties such as metabolic stability in rat plas- For administration compounds were dissolved in 3 ml/kg propylene glycol and compounds administered orally (n = 5-7 animals each). Thermal hyperalgesia and mechanical hypersensitivity were measured at 30 min intervals following oral administration as described. 14 The percentage responses noted reflect the maximum activity values from baseline to the last time point examined (120 min). ND: not detected.
Table 6
Mean pharmacokinetic parameters in rat plasma following single oral or intravenous dosing for compounds 2, 7 and 21 The N-type and L-type IC 50 columns indicate estimated IC 50 values as determined by whole-cell patch clamp of transiently expressed calcium channel complexes. For the Ltype FLIPR-based assay IC 50 values were calculated from an 8 point concentration-dependent response profile for each compound (0.003-10 lM). In those instances wherein the highest concentration (10 lM) resulted in incomplete blockade we indicate >10: 10-50% inhibition at 10 lM and )10 lM: less than 10% inhibition at 10 lM.
ma (77-91% remaining at 60 min; not shown). In these regards, and taken together with our previous report, 6 it is becoming evident that direct correlations cannot be reliably made between in vitro N-type channel blocking affinity and efficacy in neuropathic and inflammatory pain models. We hypothesize that a combination of N-type affinity, physiochemical and pharmacokinetic properties together with the underlying mechanism of N-type channel blockade by each compound (e.g., state-and frequency-dependence) likely combine to determine efficacy in pain states. In summary, optimization and structure-activity relationship studies on NP118809 have identified potent N-type calcium channel inhibitors with good selectivity against L-type calcium channels. These studies have clarified in vitro structure-activity requirements for such agents. Compounds 5 and 21 are identified as potent orally available N-type calcium channel blockers that are $12-86-fold selective over L-type calcium channels and exhibit mechanical and thermal analgesic activity in the rat spinal nerve ligation model.
